Trilogy Capital Inc. Makes New $2.02 Million Investment in Insulet Co. (NASDAQ:PODD)

Trilogy Capital Inc. bought a new position in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 7,753 shares of the medical instruments supplier’s stock, valued at approximately $2,024,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PODD. Blue Trust Inc. raised its stake in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares during the period. Venturi Wealth Management LLC raised its stake in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares during the period. TD Private Client Wealth LLC raised its stake in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the period. Friedenthal Financial acquired a new stake in shares of Insulet in the 4th quarter valued at about $57,000. Finally, Versant Capital Management Inc raised its stake in shares of Insulet by 106.1% in the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 157 shares during the period.

Insulet Trading Up 1.0 %

Shares of NASDAQ:PODD opened at $287.67 on Friday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $288.05. The stock has a market cap of $20.18 billion, a PE ratio of 49.26, a P/E/G ratio of 3.49 and a beta of 1.23. The business has a 50 day moving average of $269.95 and a 200-day moving average of $240.32. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The company had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $518.50 million. During the same quarter in the previous year, the company posted $0.71 earnings per share. As a group, equities research analysts forecast that Insulet Co. will post 3.22 earnings per share for the current year.

Insider Transactions at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PODD. Wells Fargo & Company lifted their price target on Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group lifted their target price on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. BTIG Research lifted their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. JPMorgan Chase & Co. lifted their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Finally, Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $277.13.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.